Currently, additional gene mutations have been continually identified in PAH patients by high-throughput sequencing, including activin A receptor type II-like 1 (ACVRL1), endoglin (ENG), and members of the Smad family (SMAD1, SMAD4 and SMAD9) [27]. This evidence concerns the gene ENG and pulmonary arterial hypertension.